Global Development Scientist Director, Hematology Trials

AstraZeneca; Gaithersburg (MD); Hybrid; USD 204,000 - 306,000; Full time

Benefits offered by this job

Qualified retirement programmes

Paid time off

Health, dental, and vision coverage

Incentives for performance

Equity-based awards

Sales commissions

Job summary

AstraZeneca is seeking a Global Development Scientist, Director to lead hematology trial strategy and clinical evidence generation, translating science into regulatory-ready data and publications.

You will shape pivotal protocols, drive cross-functional collaboration, and lead complex data interpretation for regulators and the medical community, with in-depth FDA/ICH knowledge and a focus on oncology assets.

Qualifications

• BS degree required; advanced degree preferred.
• 5+ years of relevant experience in drug development.
• Haematology/haemato-oncology background beneficial.
• Familiarity with FDA/ICH/GCP standards.
• Ability to lead cross-functional teams and drive protocols.

Responsibilities

• Translate disease strategy into study concepts and protocols.
• Provide clinical leadership and governance for protocols and plans.
• Design and deliver early and late phase trials with collaborators.
• Review data and interpret efficacy and safety signals for decisions.
• Contribute to regulatory submissions and lifecycle documents.
• Collaborate with regulatory bodies and external partners.
• Engage investigators and plan training to ensure quality.

Skills

Clinical development leadership

Regulatory knowledge

Cross-functional collaboration

Protocol design

Leadership

Education

BS degree

PhD/MD/PharmD preferred

Job description

AstraZeneca is seeking a Global Development Scientist, Director to lead hematology trial strategy and clinical evidence generation, translating science into regulatory-ready data and publications.

You will shape pivotal protocols, drive cross-functional collaboration, and lead complex data interpretation for regulators and the medical community, with in-depth FDA/ICH knowledge and a focus on oncology assets.